Qinlock (Ripretinib) Patent Expiration, LOE Window & CMS Spending
Qinlock (Ripretinib) by Deciphera: FDA Orange Book core substance LOE 2034-05-15 (last listed 2042-10-06), 0 AB generics, $89.2M 2024 CMS Part D & Medicaid spend, and 7 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Deciphera |
| FDA Application & Pathway | N213973 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2034-05-15 |
| Last Listed Patent or Exclusivity Date | 2042-10-06 |
| Orange Book Patents (*PED Extensions) | 42 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $89.2M |
| 2024 Medicare Part D Spend | $78.7M |
| 2024 Medicaid Spend | $10.6M |
| Reported Wholesale Price Change (CA SB 17) | 7 WAC filings (max 25.1% 2-yr change) |